Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

DNA Analysis of Blood and Tissue From Patients With Lung Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: May 8, 2007
Last updated: June 14, 2011
Last verified: June 2009

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future.

PURPOSE: This clinical trial is analyzing the DNA in blood and tissue samples from patients with lung cancer.

Condition Intervention
Lung Cancer
Genetic: polymerase chain reaction
Genetic: polymorphism analysis
Other: diagnostic laboratory biomarker analysis

Study Type: Observational
Official Title: Molecular and Genetic Analysis of Lung Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Metabolic polymorphisms [ Designated as safety issue: No ]

Estimated Enrollment: 6800
Study Start Date: September 2005
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Detailed Description:


  • Assess the role of genetic polymorphisms in lung-cancer risk in patients with lung cancer.
  • Assess the role of germline polymorphisms in DNA repair genes, p53 pathway genes, and a matrix metalloproteinase gene (tumor invasion factor) in lung-cancer risk, after adjusting for potential confounders.
  • Assess the roles of gender and age in the genetic susceptibility of lung cancer.
  • Assess the role of genetic polymorphisms in modifying the diet-lung cancer risk association (gene-diet and exploratory gene-gender-diet and gene-gene-diet interactions).
  • Assess the role of polymorphisms on the risk of developing specific histologic subtypes of lung cancer in case-only analyses.
  • Determine whether continued exposures to mainstream and/or second-hand tobacco smoking is associated with poorer clinical prognosis in patients treated for lung cancer.

OUTLINE: This is a case-control study.

Blood samples are collected from patients and controls. Samples are analyzed by polymerase chain reaction for gene polymorphisms. Genes to be studied include GSTP1, GSTM1, GSTT1, ERCC2, XRCC1, EPHX, NAT-2, p53 gene, CYP1A1, NQO1, MnSOD, and GPX1. Tissue samples collected from patients undergoing surgery and blood samples are archived for future studies.

Patients and controls complete questionnaires about diet, medical history, and occupational/environmental history.

PROJECTED ACCRUAL: A total of 3,400 patients and 3,400 controls will be accrued for this study.


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Patient:

    • Newly diagnosed lung cancer

      • Patient at Massachusetts General Hospital (MGH) or Boston Medical Center Cancer Center
  • Control:

    • Nonblood-related friend or spouse of the patient

      • No specific matching characteristics
    • Friend or spouse of other hospital patients


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00471978

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Harvard School of Public Health
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
National Cancer Institute (NCI)
Principal Investigator: David C. Christiani, MD Massachusetts General Hospital
  More Information Identifier: NCT00471978     History of Changes
Other Study ID Numbers: CDR0000450128  MGH-1999-P-004935/26  MGH-90-7197 
Study First Received: May 8, 2007
Last Updated: June 14, 2011
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
non-small cell lung cancer
small cell lung cancer
pulmonary carcinoid tumor

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases processed this record on December 08, 2016